These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 9778326

  • 1. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists.
    Storey RF, Wilcox RG, Heptinstall S.
    Circulation; 1998 Oct 20; 98(16):1616-21. PubMed ID: 9778326
    [Abstract] [Full Text] [Related]

  • 2. A whole blood assay of inhibition of platelet aggregation by glycoprotein IIb/IIIa antagonists: comparison with other aggregation methodologies.
    Storey RF, May JA, Wilcox RG, Heptinstall S.
    Thromb Haemost; 1999 Oct 20; 82(4):1307-11. PubMed ID: 10544919
    [Abstract] [Full Text] [Related]

  • 3. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ, Jordan RE, Mascelli MA.
    Thromb Haemost; 2001 Mar 20; 85(3):539-43. PubMed ID: 11307828
    [Abstract] [Full Text] [Related]

  • 4. P2Y12 receptor blockade augments glycoprotein IIb-IIIa antagonist inhibition of platelet activation, aggregation, and procoagulant activity.
    Berny-Lang MA, Jakubowski JA, Sugidachi A, Barnard MR, Michelson AD, Frelinger AL.
    J Am Heart Assoc; 2013 May 15; 2(3):e000026. PubMed ID: 23676293
    [Abstract] [Full Text] [Related]

  • 5. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.
    Phillips DR, Teng W, Arfsten A, Nannizzi-Alaimo L, White MM, Longhurst C, Shattil SJ, Randolph A, Jakubowski JA, Jennings LK, Scarborough RM.
    Circulation; 1997 Sep 02; 96(5):1488-94. PubMed ID: 9315536
    [Abstract] [Full Text] [Related]

  • 6. Upregulation of GP IIb/IIIa receptors during platelet activation: influence on efficacy of receptor blockade.
    Matzdorff A, Voss R.
    Thromb Res; 2006 Sep 02; 117(3):307-14. PubMed ID: 15894353
    [Abstract] [Full Text] [Related]

  • 7. The in vitro effect of eptifibatide, a glycoprotein IIb/IIIa antagonist, on various responses of porcine blood platelets.
    Ciborowski M, Tomasiak M.
    Acta Pol Pharm; 2009 Sep 02; 66(3):235-42. PubMed ID: 19645323
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide.
    Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T.
    Am Heart J; 2002 Apr 02; 143(4):585-93. PubMed ID: 11923794
    [Abstract] [Full Text] [Related]

  • 9. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S, Lassila R.
    Thromb Res; 2006 Apr 02; 117(3):291-7. PubMed ID: 15878612
    [Abstract] [Full Text] [Related]

  • 10. Comparison of GP IIB/IIIA inhibitors and their activity as measured by aggregometry, flow cytometry, single platelet counting, and the rapid platelet function analyzer.
    Matzdorff AC, Kühnel G, Kemkes-Matthes B, Voss R.
    J Thromb Thrombolysis; 2001 Oct 02; 12(2):129-39. PubMed ID: 11729364
    [Abstract] [Full Text] [Related]

  • 11. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.
    Circulation; 2002 Sep 17; 106(12):1470-6. PubMed ID: 12234950
    [Abstract] [Full Text] [Related]

  • 12. Role of extracellular ionized calcium in the in vitro assessment of GPIIb/IIIa receptor antagonists.
    Rebello SS, Huang J, Faul JD, Lucchesi BR.
    J Thromb Thrombolysis; 2000 Jan 17; 9(1):23-8. PubMed ID: 10590185
    [Abstract] [Full Text] [Related]

  • 13. Greater inhibition of platelet procoagulant activity by antibody-derived glycoprotein IIb--IIIa inhibitors than by peptide and peptidomimetic inhibitors.
    Lages B, Weiss HJ.
    Br J Haematol; 2001 Apr 17; 113(1):65-71. PubMed ID: 11328283
    [Abstract] [Full Text] [Related]

  • 14. Clinical pharmacology of eptifibatide.
    Phillips DR, Scarborough RM.
    Am J Cardiol; 1997 Aug 18; 80(4A):11B-20B. PubMed ID: 9291241
    [Abstract] [Full Text] [Related]

  • 15. Anti-platelet and anti-thrombosis characteristics of Z4A5, a novel selective platelet glycoprotein IIb/IIIa inhibitor, compared with eptifibatide under long-term infusion.
    Shi XL, Shen S, Guo MM, Zhang GJ, Che J, Wang B, Zhou J.
    Pharmazie; 2015 Dec 18; 70(12):810-4. PubMed ID: 26817279
    [Abstract] [Full Text] [Related]

  • 16. In vitro dose response to different GPIIb/IIIa-antagonists: inter-laboratory comparison of various platelet function tests.
    Harder S, Klinkhardt U, Graff J, Westrup D, Kirchmaier CM, Glusa E, Mascelli MA, Marciniak SJ, Just A, Lösche W, Breddin HK.
    Thromb Res; 2001 Apr 01; 102(1):39-48. PubMed ID: 11323013
    [Abstract] [Full Text] [Related]

  • 17. Identification of low molecular weight GP IIb/IIIa antagonists that bind preferentially to activated platelets.
    Bednar RA, Gaul SL, Hamill TG, Egbertson MS, Shafer JA, Hartman GD, Gould RJ, Bednar B.
    J Pharmacol Exp Ther; 1998 Jun 01; 285(3):1317-26. PubMed ID: 9618439
    [Abstract] [Full Text] [Related]

  • 18. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L, Alves VL, Phillips DR.
    Circulation; 2003 Mar 04; 107(8):1123-8. PubMed ID: 12615789
    [Abstract] [Full Text] [Related]

  • 19. The GPIIb/IIIa antagonist eptifibatide markedly potentiates platelet-leukocyte interaction and tissue factor expression following platelet activation in whole blood in vitro.
    Scholz T, Zhao L, Temmler U, Bath P, Heptinstall S, Lösche W.
    Platelets; 2002 Nov 04; 13(7):401-6. PubMed ID: 12487787
    [Abstract] [Full Text] [Related]

  • 20. The effect of glycoprotein IIIa PIA 1/A2 polymorphism on the PFA-100 response to GP IIb IIa receptor inhibitors-the importance of anticoagulants used.
    Aalto-Setälä K, Karhunen PJ, Mikkelsson J, Niemelä K.
    J Thromb Thrombolysis; 2005 Aug 04; 20(1):57-63. PubMed ID: 16133898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.